BioMarin Down on CRL From FDA for Hemophilia A Candidate. Here’s Why. Factset: FactSet Research Systems Inc.2019. Industrial Estate, Port Glasgow, Renfrewshire PA14 5XG. For the best MarketWatch.com experience, please update to a modern browser. CNN Sans™ & © 2016 Cable News Network. BioMarin Stock Slumps After FDA’s Surprise Rejection of a Hemophilia Gene Therapy, Biogen profit and sales top estimates in Q1, Sangamo Stock Is Soaring on Plan to Collaborate With Biogen. Is Sangamo Therapeutics, Inc. (SGMO) A Good Stock To Buy? Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences: Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGS - NasdaqGS Real Time Price. This NYC Startup Raises $51M to Disrupt the Retirement Industry, 20 Questions to Know If You're Ready for Retirement, 7 Mistakes That Will Ruin Your Retirement Income, 7 Retirement Secrets Smart Americans Should Know, You Can Still Buy This "Millionaire Maker" Stock, Bitcoin Up 30,000X -- Here's Your Backdoor In, This Stock Could Be Like Buying Amazon for $3.19. Intraday Data provided by FACTSET and subject to terms of use. VAT No: GB 804 5673 30 Sangamo Therapeutics, Inc. Common Stock (SGMO) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Have Watchlists? We at Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. Historical and current end-of-day data provided by FACTSET. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. BioMarin Stock’s Near-Term Growth Is Gone, Analyst Says. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA. Apple Stock, Boeing Are Dropping and the Dow Looks Set to Slip, Sangamo's stock soars after upbeat trial data for hemophilia treatment, Gene-therapy stocks surge on Roche-Spark deal, Cutting-edge biotech Sangamo stock dives 12% after JPMorgan cites ‘growing skepticism’ in downgrade, Sangamo stock drops after J.P. Morgan downgrade, Sangamo Therapeutics stock drops 24% on results of cutting-edge gene-editing trial, U.S. stocks close mostly lower as tech sector has worst day in over a month, Sangamo stock drops 13% premarket on results of phase 1/2 gene editing trial, Sangamo Therapeutics shares fall on announced secondary offering, S&P 500 stalls at the breakdown point, back for another crack at 200-day average, Sarepta: Leading The Genomic Medicine Pack, Pfizer commences late-stage study of hemophilia A gene therapy, Sangamo: $665M In Cash Ready To Be Deployed Across A Pipeline Of 18 Therapeutics And 2 New 2020 Partnerships, 29% Upside, These Are The Four Biotech Stocks Recently Pitched At The Ira Sohn Conference, BioMarin Declining Factor Levels Unlikely To Impact Uniqure Or Sangamo Phase 3 Hemophilia Trials.